Serina Therapeutics Inc 2025年季度报告

FORM10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedSeptember 30, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number1-38519 Serina Therapeutics, Inc. (Exact name of registrant as specified in its charter) 82-1436829(I.R.S. EmployerIdentification No.) Delaware (State or other jurisdiction ofincorporation or organization) 601 Genome Way,Suite 2001Huntsville,Alabama35806(Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code:(256)327-9630 Name of exchange on which registered NYSEAmerican Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.xYesoNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).xYesoNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated fileroAccelerated fileroNon-accelerated filerxSmaller reporting companyxEmerging growth companyo If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).oYesxNo The number of shares common stock outstanding as of November10, 2025 was10,664,064, par value $0.0001 per share. SERINA THERAPEUTICS, INC.TABLE OF CONTENTS PageNumberPart I – FINANCIAL INFORMATIONItem 1.Financial Statements4Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations29Item 3.Quantitative and Qualitative Disclosures About Market Risk37Item 4.Controls and Procedures38 Item 1.Legal Proceedings40Item 1A.Risk Factors40Item 2.Unregistered Sales of Equity Securities and Use of Proceeds44Item 3.Default Upon Senior Securities44Item 4.Mine Safety Disclosures44Item 5.Other Information45Item 6.Exhibits45 Forward-Looking Statements This Quarterly Report on Form 10-Q (“Report”) contains forward-looking statements that involve risks and uncertainties. We makesuch forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 andother federal securities laws. All statements other than statements of historical facts contained in this Report are forward-lookingstatements. In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe,” “contemplate,”“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,”“will,” “would,” or the negative of these words or other comparable terminology. Any forward-looking statements in this Report reflect our current views with respect to future events or to our future financialperformance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance orachievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things,those discussed in this Report under Item 1 of the Notes to Condensed Consolidated Financial Statements, under Risk Factors in thisReport, those incorporated by reference in the section titled “Risk Factors" in our Annual Report on Form 10-K and our otherperiodic reports and documents filed from time to time with the SEC. Given these uncertainties, you should not place undue relianceon these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-lookingstatements for any reason, even if new information becomes available in the future. The description or discussion, in this Report, of any contract or agreement is a summary only and is qualified in all respects byreference to the full text of the applicable contract or agreement. As used herein, otherwise